Wolfe Research analyst Andy Chen initiated coverage of Vertex Pharmaceuticals with an Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex announces EC grants conditional marketing authorization to Casgevy
- Vertex Pharmaceuticals price target raised to $465 from $420 at Argus
- Crispr Therapeutics price target lowered to $120 from $160 at Truist
- Vertex Pharmaceuticals price target lowered to $371 from $378 at Canaccord
- Vertex Pharmaceuticals price target raised to $472 from $446 at Barclays